☆ 4.7 Article

Full-Lung Prophylaxis against SARS-CoV-2 by One-Shot or Booster Intranasal Lentiviral Vaccination in Syrian Golden Hamsters

VACCINES (2023)

Related references

Note: Only part of the references are listed.

Article Biochemistry & Molecular Biology

Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination

Katharina Roltgen et al.

Summary: During the SARS-CoV-2 pandemic, different vaccines have been used globally. This study compares the antibodies generated by mRNA vaccines, infection, and other types of vaccines. It shows that mRNA vaccines result in a better antibody breadth against viral variants compared to infection. Infection leads to variant-specific antibodies, while mRNA vaccination imprints responses towards the original virus strain. mRNA vaccines also stimulate robust germinal centers in lymph nodes, enhancing the immune response.

CELL (2022)

Add to Collection

Article Biochemistry & Molecular Biology

Respiratory mucosal delivery of next-generation COVID-19 vaccine provides robust protection against both ancestral and variant strains of SARS-CoV-2

Sam Afkhami et al.

Summary: The study found that using adenoviral vectors with a multivalent vaccine through intranasal immunization can generate better mucosal immune responses, including local and systemic antibody responses, mucosal tissue-resident memory T cells, and mucosal trained innate immunity, and provide protection against multiple viral variants.

CELL (2022)

Add to Collection

Letter Medicine, General & Internal

Breakthrough infections with SARS-CoV-2 omicron despite mRNA vaccine booster dose

Constanze Kuhlmann et al.

LANCET (2022)

Add to Collection

Review Biotechnology & Applied Microbiology

Adenovirus-based vaccines-a platform for pandemic preparedness against emerging viral pathogens

Lynda Coughlan et al.

Summary: Zoonotic viruses pose a continuous threat, and investing in vaccine development is crucial. Replication-defective adenoviral vectors have shown potential as vaccine platforms. This review discusses the progress in using Ad-based vaccines against emerging viruses and summarizes their global safety profile during the SARS-CoV-2 pandemic.

MOLECULAR THERAPY (2022)

Add to Collection

Article Multidisciplinary Sciences

Considerable escape of SARS-CoV-2 Omicron to antibody neutralization

Delphine Planas et al.

Summary: The Omicron variant of SARS-CoV-2, identified in November 2021, has spread rapidly worldwide and shows resistance to most therapeutic monoclonal antibodies and vaccine-elicited antibodies. However, it can be neutralized by antibodies generated by a booster vaccine dose.

NATURE (2022)

Add to Collection

Article Immunology

Pan-SARS neutralizing responses after third boost vaccination in non-human primate immunogenicity model

Kirill Kalnin et al.

Summary: The study evaluated the efficacy of different types of mRNA vaccines in inducing neutralizing antibodies against SARS-CoV-2 variants in nonhuman primates. The results showed that a third vaccination significantly increased neutralizing antibody titers and expanded the coverage to more variants, regardless of the type of vaccine previously administered.

VACCINE (2022)

Add to Collection

Article Immunology

Omicron variant showed lower neutralizing sensitivity than other SARS-CoV-2 variants to immune sera elicited by vaccines after boost

Jingwen Ai et al.

Summary: This study explored the immunogenicity of different vaccination strategies against the Omicron variant of SARS-CoV-2. The results showed that the Omicron variant has a high immune escape ability compared to other variants, but heterologous protein subunit vaccines and homologous inactivated vaccine boosters can improve neutralization against Omicron.

EMERGING MICROBES & INFECTIONS (2022)

Add to Collection

Article Immunology

SARS-CoV-2 Spike-Specific CD4+T Cell Response Is Conserved Against Variants of Concern, Including Omicron

Alessio Mazzoni et al.

Summary: This study found that previous Alpha variant infection can reactivate CD4+ T cell memory, and most Spike-specific CD4+ T cell responses are conserved against SARS-CoV-2 variants, providing an effective defense against the development of severe COVID-19.

FRONTIERS IN IMMUNOLOGY (2022)

Add to Collection

Article Medicine, General & Internal

Safety and immunogenicity of a measles-vectored SARS-CoV-2 vaccine candidate, V591/TMV-083, in healthy adults: results of a randomized, placebo-controlled Phase I study

Odile Launay et al.

Summary: This study conducted a randomized, placebo-controlled Phase I trial in France and Belgium to evaluate the safety and immunogenicity of V591, a measles vector-based vaccine candidate for COVID-19. The results showed that V591 had a good safety profile at both dose levels, but the immunogenicity was not sufficient to support further development.

EBIOMEDICINE (2022)

Add to Collection

Article Biotechnology & Applied Microbiology

An intranasal lentiviral booster reinforces the waning mRNA vaccine-induced SARS-CoV-2 immunity that it targets to lung mucosa

Benjamin Vesin et al.

Summary: For COVID-19, intranasal boosting with LV::SBeta-2P vaccine can effectively enhance cross-sero-neutralizing activity and systemic T cell immunity. In addition, the vaccine efficiently induces mucosal antibodies, lung-resident B cells, and effector memory and resident T cells, providing protection against both SARS-CoV-2 Delta variant and Omicron infection in the lungs.

MOLECULAR THERAPY (2022)

Add to Collection

Article Cell Biology

Adenovirus type 5 SARS-CoV-2 vaccines delivered orally or intranasally reduced disease severity and transmission in a hamster model

Stephanie N. Langel et al.

Summary: Vaccination through oral or intranasal routes can generate strong antibody responses, reduce viral load in the nose and lungs, and mitigate lung pathology caused by SARS-CoV-2. Mucosally vaccinated hamsters transmitted fewer viruses with less severity to naive hamsters, suggesting that mucosal immunization can reduce viral transmission. In a clinical trial, the same platform also induced mucosal cross-reactive antibody responses.

SCIENCE TRANSLATIONAL MEDICINE (2022)

Add to Collection

Article Cell Biology

Efficacy of vaccination and previous infection against the Omicron BA.1 variant in Syrian hamsters

Peter J. Halfmann et al.

Summary: Antigenic changes in the Omicron variant lead to vaccine breakthrough and reinfection, with the Moderna mRNA vaccine showing reduced efficacy against this variant.

CELL REPORTS (2022)

Add to Collection

Article Multidisciplinary Sciences

Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure

Catherine J. Reynolds et al.

Summary: This study investigated the immune response of triple BioNTech BNT162b2 mRNA-vaccinated healthcare workers to the B.1.1.529 variant. It was found that individuals vaccinated with three doses showed enhanced immunity against previous variants, but reduced immune response to B.1.1.529. Individuals previously infected with other variants showed enhanced immunity against earlier variants, but reduced immune response to B.1.1.529.

SCIENCE (2022)

Add to Collection

Article Cell Biology

A lentiviral vector encoding fusion of light invariant chain and mycobacterial antigens induces protective CD4+ T cell immunity

Jodie Lopez et al.

Summary: In this study, a strategy was devised to enhance the CD4(+) T cell response of Lentiviral vectors (LVs) by extending the LV-encoded antigens with MHC-II-associated light invariant chain. The results showed that this strategy improved the protective efficacy against Mycobacterium tuberculosis and extended the mucosal immune response.

CELL REPORTS (2022)

Add to Collection

Article Immunology

Respiratory mucosal immunity against SARS-CoV-2 after mRNA vaccination

Jinyi Tang et al.

Summary: SARS-CoV-2 mRNA vaccination induces strong immune responses in the circulation, but its effectiveness in the respiratory tract, especially against variants of concern like Omicron, is still uncertain. This study found lower neutralizing antibody responses in the respiratory tract of vaccinated individuals compared to COVID-19 convalescents, despite robust antibody responses in the blood. Vaccination also induced circulating B and T cell immunity, but these responses were absent in the respiratory tract. Mouse immunization experiments showed that systemic mRNA vaccination alone resulted in weak respiratory mucosal neutralizing antibody responses, but combining it with mucosal adenovirus-S immunization produced strong neutralizing antibody responses against both the ancestral virus and the Omicron variant. Overall, this study suggests that current COVID-19 vaccines are highly effective against severe disease, but provide limited protection against breakthrough infections, particularly by the Omicron sublineage.

SCIENCE IMMUNOLOGY (2022)

Add to Collection

Article Microbiology

Intranasal vaccination with a lentiviral vector protects against SARS-CoV-2 in preclinical animal models

Min-Wen Ku et al.

Summary: Vaccination using a lentiviral vector to induce neutralizing antibodies against SARS-CoV-2 provides partial protection when administered systemically, but intranasal immunization results in a significant decrease in lung viral load and reduced local inflammation. Integrative and non-integrative lentiviral platforms both show strong vaccine efficacy against COVID-19 in golden hamsters, highlighting the potential of intranasal vaccination as a powerful approach.

CELL HOST & MICROBE (2021)

Add to Collection

Article Medicine, Research & Experimental

Brain cross-protection against SARS-CoV-2 variants by a lentiviral vaccine in new transgenic mice

Min-Wen Ku et al.

Summary: Research has shown that using a non-integrative lentiviral vector to inject the spike glycoprotein of the ancestral SARS-CoV-2 can provide sterilizing protection of the lung and brain against both the ancestral virus and the Gamma variant carrying multiple vaccine escape mutations.

EMBO MOLECULAR MEDICINE (2021)

Add to Collection

Article Immunology

Use of lentiviral vectors in vaccination

Min-Wen Ku et al.

Summary: Lentiviral vectors are powerful tools for vaccination, with high efficiency in transducing dendritic cells and inducing long-lasting humoral immunity. They are non-replicative, minimally inflammatory, and novel targets for vaccine development, showing potential in prophylaxis against infectious diseases and onco-immunotherapy.

EXPERT REVIEW OF VACCINES (2021)

Add to Collection

Article Cell Biology

Enhanced SARS-CoV-2 neutralization by dimeric IgA

Zijun Wang et al.

Summary: The IgA response to SARS-CoV-2 was characterized in a cohort of 149 convalescent individuals after COVID-19 diagnosis. IgA responses in plasma generally correlated with IgG responses, and B cells producing IgM, IgG, and IgA were derived from common progenitor cells. Notably, IgA dimers were found to be 15 times more potent than IgA monomers against SARS-CoV-2, suggesting their potential value for protection and vaccine efficacy.

SCIENCE TRANSLATIONAL MEDICINE (2021)

Add to Collection

Article Cell Biology

IgA dominates the early neutralizing antibody response to SARS-CoV-2

Delphine Sterlin et al.

Summary: The study found that humoral immune responses to SARS-CoV-2 infection are dominated by IgA antibodies, with specific IgA plasmablasts rapidly expanding shortly after symptom onset and peaking in the third week of the disease. Virus-specific antibody responses include IgG, IgM, and IgA, with IgA playing a greater role in virus neutralization compared to IgG.

SCIENCE TRANSLATIONAL MEDICINE (2021)

Add to Collection

Article Multidisciplinary Sciences

Detection of a SARS-CoV-2 variant of concern in South Africa

Houriiyah Tegally et al.

Summary: The article describes a newly emerged lineage of SARS-CoV-2, 501Y.V2, characterized by eight mutations in the spike protein, which may result in increased transmissibility or immune escape. This lineage originated in South Africa and quickly became dominant in Eastern Cape, Western Cape, and KwaZuluNatal provinces within weeks.

NATURE (2021)

Add to Collection

Article Multidisciplinary Sciences

SARS CoV-2 Delta variant exhibits enhanced infectivity and a minor decrease in neutralization sensitivity to convalescent or post-vaccination sera

Alona Kuzmina et al.

Summary: The study found that both Delta and Kappa variants were successfully neutralized by convalescent and post-vaccination sera, with Delta variant showing higher infectivity levels. The Delta plus variant exhibited high resistance to post-vaccination sera, similar to the Beta variant, but had infectivity levels close to the wild-type SARS-CoV-2.

ISCIENCE (2021)

Add to Collection

Letter Medicine, General & Internal

Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants

Laith J. Abu-Raddad et al.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Virology

The Potential of Neuraminidase as an Antigen for Nasal Vaccines To Increase Cross-Protection against Influenza Viruses

Atsushi Kawai et al.

Summary: The study demonstrates that intranasal immunization with NA provides broad cross-protection against both homologous and heterologous influenza viruses by inducing NA-specific IgA that recognizes a wider range of epitopes, indicating the potential of NA as an antigen for nasal vaccines to provide broad cross-protection.

JOURNAL OF VIROLOGY (2021)

Add to Collection

Article Cell Biology

Intranasal ChAdOx1 nCoV-19/AZD1222 vaccination reduces viral shedding after SARS-CoV-2 D614G challenge in preclinical models

Neeltje van Doremalen et al.

Summary: Intranasal vaccination with ChAdOx1 nCoV-19/AZD1222 reduced viral loads in nasal swabs in vaccinated macaques and hamsters challenged with SARS-CoV-2, indicating potential for further investigation as a vaccination route for COVID-19 vaccines.

SCIENCE TRANSLATIONAL MEDICINE (2021)

Add to Collection

Article Cell Biology

A single intranasal or intramuscular immunization with chimpanzee adenovirus-vectored SARS-CoV-2 vaccine protects against pneumonia in hamsters

Traci L. Bricker et al.

Summary: The study found that intranasal administration provides superior protection against SARS-CoV-2 infection and inflammation in the upper respiratory tract compared to intramuscular injection, reducing weight loss, viral infection, and lung pathology. Therefore, intranasal delivery of ChAd-SARS-CoV-2-S candidate vaccine is supported for preventing SARS-CoV-2 infection.

CELL REPORTS (2021)

Add to Collection

Article Public, Environmental & Occupational Health

Effectiveness of COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Frontline Workers Before and During B.1.617.2 (Delta) Variant Predominance — Eight U.S. Locations, December 2020–August 2021

Ashley Fowlkes et al.

MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2021)

Add to Collection

Article Infectious Diseases

Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR

Victor M. Corman et al.

EUROSURVEILLANCE (2020)

Add to Collection

Article Microbiology

The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2

Alexander E. Gorbalenya et al.

NATURE MICROBIOLOGY (2020)

Add to Collection

Article Immunology

Surgical Mask Partition Reduces the Risk of Noncontact Transmission in a Golden Syrian Hamster Model for Coronavirus Disease 2019 (COVID-19)

Jasper Fuk-Woo Chan et al.

CLINICAL INFECTIOUS DISEASES (2020)

Add to Collection

Article Biotechnology & Applied Microbiology

A Single Dose of NILV-Based Vaccine Provides Rapid and Durable Protection against Zika Virus

Min Wen Ku et al.

MOLECULAR THERAPY (2020)

Add to Collection

Article Multidisciplinary Sciences

Pathogenesis and transmission of SARS-CoV-2 in golden hamsters

Sin Fun Sia et al.

NATURE (2020)

Add to Collection

Article Multidisciplinary Sciences

Virological assessment of hospitalized patients with COVID-2019

Roman Woelfel et al.

NATURE (2020)

Add to Collection

Article Infectious Diseases

Clinical and virological data of the first cases of COVID-19 in Europe: a case series

Francois-Xavier Lescure et al.

LANCET INFECTIOUS DISEASES (2020)

Add to Collection

Article Biochemistry & Molecular Biology

Structure-guided covalent stabilization of coronavirus spike glycoprotein trimers in the closed conformation

Matthew McCallum et al.

NATURE STRUCTURAL & MOLECULAR BIOLOGY (2020)

Add to Collection

Article Multidisciplinary Sciences

Structure-based design of prefusion-stabilized SARS-CoV-2 spikes

Ching-Lin Hsieh et al.

SCIENCE (2020)

Add to Collection

Review Multidisciplinary Sciences

Animal models for COVID-19

Cesar Munoz-Fontela et al.

NATURE (2020)

Add to Collection

Article Infectious Diseases

How to assess the effectiveness of nasal influenza vaccines? Role and measurement of sIgA in mucosal secretions

Elena Gianchecchi et al.

INFLUENZA AND OTHER RESPIRATORY VIRUSES (2019)

Add to Collection

Article Multidisciplinary Sciences

Potent protection against H5N1 and H7N9 influenza via childhood hemagglutinin imprinting

Katelyn M. Gostic et al.

SCIENCE (2016)

Add to Collection

Review Virology

Understanding and altering cell tropism of vesicular stomatitis virus

Eric Hastie et al.

VIRUS RESEARCH (2013)

Add to Collection

Article Multidisciplinary Sciences

A Nonintegrative Lentiviral Vector-Based Vaccine Provides Long-Term Sterile Protection against Malaria

Frederic Coutant et al.

PLOS ONE (2012)

Add to Collection

Article Biotechnology & Applied Microbiology

A single immunization with a minute dose of a lentiviral vector-based vaccine is highly effective at eliciting protective humoral immunity against West Nile virus

Maria Candela Iglesias et al.

JOURNAL OF GENE MEDICINE (2006)

Add to Collection

© Peeref 2019-2024. All rights reserved.